Atria Investments Inc Has $3.08 Million Stock Position in Insmed, Inc. $INSM

Atria Investments Inc boosted its holdings in shares of Insmed, Inc. (NASDAQ:INSM) by 27.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,413 shares of the biopharmaceutical company’s stock after purchasing an additional 4,603 shares during the period. Atria Investments Inc’s holdings in Insmed were worth $3,084,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Yousif Capital Management LLC bought a new stake in Insmed during the 2nd quarter worth about $201,000. Sagespring Wealth Partners LLC acquired a new position in shares of Insmed during the second quarter worth approximately $254,000. Allianz Asset Management GmbH lifted its position in shares of Insmed by 6.8% during the second quarter. Allianz Asset Management GmbH now owns 80,422 shares of the biopharmaceutical company’s stock worth $8,094,000 after purchasing an additional 5,138 shares in the last quarter. Stratos Wealth Partners LTD. bought a new stake in shares of Insmed during the second quarter valued at approximately $223,000. Finally, Mutual of America Capital Management LLC increased its holdings in shares of Insmed by 9.3% in the second quarter. Mutual of America Capital Management LLC now owns 86,492 shares of the biopharmaceutical company’s stock valued at $8,705,000 after purchasing an additional 7,351 shares in the last quarter.

Insider Activity

In related news, COO Roger Adsett sold 791 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $156.17, for a total transaction of $123,530.47. Following the completion of the sale, the chief operating officer directly owned 106,810 shares of the company’s stock, valued at approximately $16,680,517.70. This represents a 0.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Michael Alexander Smith sold 640 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $156.27, for a total transaction of $100,012.80. Following the sale, the insider owned 56,397 shares in the company, valued at $8,813,159.19. This trade represents a 1.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 173,253 shares of company stock worth $29,629,842 in the last 90 days. Corporate insiders own 3.00% of the company’s stock.

Insmed Stock Performance

Shares of NASDAQ:INSM opened at $148.75 on Monday. The firm’s 50 day simple moving average is $169.05 and its 200 day simple moving average is $162.29. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $212.75. The company has a market capitalization of $31.72 billion, a price-to-earnings ratio of -24.03 and a beta of 1.11. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Citigroup reiterated an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Truist Financial set a $205.00 price target on Insmed in a report on Monday, January 12th. Mizuho set a $212.00 price objective on Insmed in a research report on Thursday, December 18th. Barclays assumed coverage on shares of Insmed in a research report on Tuesday, January 27th. They set an “overweight” rating and a $231.00 target price on the stock. Finally, HC Wainwright lowered their price target on shares of Insmed from $240.00 to $230.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Insmed currently has an average rating of “Buy” and an average price target of $204.24.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.